Myopia — or nearsightedness — has reached epidemic proportions globally, and the Hudson Valley is no exception. Currently affecting roughly 50% of the population and projected to reach 50% of the world's children by 2050, myopia is no longer simply a matter of needing glasses to see the board at school. It's a significant and growing public health concern, and Harnos Optometry in New Paltz, NY is at the forefront of addressing it with evidence-based myopia management programs for children.
Why Myopia Management Matters Beyond Glasses
The critical distinction between standard myopia correction and myopia management is this: glasses and conventional contacts correct the blurriness of myopia, but they do nothing to slow the underlying process of eye elongation that causes it. A child who goes from -1.00 to -5.00 over eight years of wearing glasses hasn't been managed — they've simply been corrected while the problem progressed unchecked.
High myopia (typically defined as -6.00 diopters or higher) carries significantly elevated lifetime risks of serious eye disease. The longer the eye grows, the more the retina stretches and thins — dramatically increasing the lifetime risk of:
- ◆Retinal detachment (risk increased up to 10x in high myopia)
- ◆Myopic macular degeneration
- ◆Glaucoma (risk increased 2–3x in high myopia)
- ◆Cataracts developing at an earlier age
Every diopter of myopia progression prevented during childhood reduces these lifetime risks meaningfully. That's the goal of myopia management — not just clearer vision today, but healthier eyes for decades to come.
Our Myopia Management Toolkit
At Harnos Optometry, we offer the full range of evidence-based myopia control treatments, customized to each child's prescription, lifestyle, and family preferences:
- ◆Orthokeratology (Ortho-K) — overnight corneal reshaping lenses that provide clear daytime vision without glasses while reducing axial elongation by 30–60%
- ◆MiSight or peripheral defocus contact lenses — specially designed soft lenses worn during the day that correct central vision while creating peripheral defocus to inhibit eye growth
- ◆Low-dose atropine eye drops — nightly drops that reduce the accommodative signal driving eye elongation; the most studied myopia control intervention with well-established efficacy
- ◆Combination therapy — for higher-risk patients, combining atropine with Ortho-K or peripheral defocus lenses provides the strongest available evidence of effect
If your child's prescription is increasing annually, now is the time to act. The earlier myopia management begins, the more total progression can be prevented. Schedule a myopia management consultation at Harnos Optometry in New Paltz today.